BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther. 2006;24:781-788. [PMID: 16918881 DOI: 10.1111/j.1365-2036.2006.03041.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
2 Yoo JJ, Lee JH, Yoon JH, Lee M, Lee DH, Cho Y, Jang ES, Cho EJ, Yu SJ, Kim YJ, Lee HS. Hepatitis B virus-related glomerulonephritis: not a predominant cause of proteinuria in korean patients with chronic hepatitis B. Gastroenterol Res Pract 2015;2015:126532. [PMID: 25788940 DOI: 10.1155/2015/126532] [Reference Citation Analysis]
3 Yang YM, Choi EJ. Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection. Ther Clin Risk Manag. 2017;13:1273-1285. [PMID: 29033575 DOI: 10.2147/tcrm.s143286] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
4 Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, Schmutz G, Herrmann E. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011;55:1235-1240. [PMID: 21703180 DOI: 10.1016/j.jhep.2011.03.030] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
5 Pipili CL, Papatheodoridis GV, Cholongitas EC. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int. 2013;84:880-885. [PMID: 23783238 DOI: 10.1038/ki.2013.249] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
6 Liu Y, Shi C, Fan J, Wang B, Li G. Hepatitis B-related glomerulonephritis and optimization of treatment. Expert Rev Gastroenterol Hepatol 2020;14:113-25. [PMID: 31951758 DOI: 10.1080/17474124.2020.1717948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cacoub P, Asselah T. Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease. Am J Gastroenterol 2021. [PMID: 34913875 DOI: 10.14309/ajg.0000000000001575] [Reference Citation Analysis]
8 Chaabane NB, Loghmari H, Melki W, Hellara O, Safer L, Bdioui F, Saffar H. [Chronic viral hepatitis and kidney failure]. Presse Med 2008;37:665-78. [PMID: 18291615 DOI: 10.1016/j.lpm.2007.10.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
9 Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Fabrizi F, Cerutti R, Ridruejo E. Hepatitis B virus infection as a risk factor for chronic kidney disease. Expert Rev Clin Pharmacol 2019;12:867-74. [PMID: 31456441 DOI: 10.1080/17512433.2019.1657828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Ladapo TA, Onifade EU, Lesi AE, Lesi OA. Successful Treatment of Hepatitis B Virus Associated Nephrotic Syndrome With Oral Lamivudine in a Nigerian Child: A Case Report. Journal of Tropical Pediatrics 2012;58:157-8. [DOI: 10.1093/tropej/fmr046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Peters MG. Special populations with hepatitis B virus infection. Hepatology. 2009;49:S146-S155. [PMID: 19399810 DOI: 10.1002/hep.22965] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
13 Shah HH, Patel C, Jhaveri KD. Complete Remission of Hepatitis B Virus-Associated Nephrotic Syndrome from IgA Nephropathy Following Peginterferon Therapy. Renal Failure 2012;35:295-8. [DOI: 10.3109/0886022x.2012.745785] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
14 Terrier B, Cacoub P. Virus de l’hépatite B, manifestations extrahépatiques immunologiques et risque de réactivation virale. La Revue de Médecine Interne 2011;32:622-7. [DOI: 10.1016/j.revmed.2010.08.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
15 Nan Y, Hong S, Niu X, Li W, Zhao S, Wang R, Zhang Y. Telbivudine protects against renal impairment in patients with chronic hepatitis B infection. Future Virology 2016;11:219-32. [DOI: 10.2217/fvl-2015-0015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1014] [Article Influence: 153.7] [Reference Citation Analysis]
17 Sathyanarayanan V, Razak A, Narayan G, Prabhu M, Ramachandran B, Ranjini K, Vidya M, Joshi K. Posterior reversible encephalopathy syndrome in a patient with hepatitis B induced type 1 membranoproliferative glomerulonephritis. Clin Exp Nephrol 2010;14:614-8. [PMID: 20730470 DOI: 10.1007/s10157-010-0331-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Zhang Y, Zhou JH, Yin XL, Wang FY. Treatment of hepatitis B virus-associated glomerulonephritis: A meta-analysis. World J Gastroenterol 2010; 16(6): 770-777 [PMID: 20135728 DOI: 10.3748/wjg.v16.i6.770] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
19 Yang DK, Sun YF, Liang HJ, Shen BS, Qiao HC. Treatment of hepatitis B virus-associated glomerulonephritis with compound glycyrrhizin and lamivudine: an analysis of 40 cases. Shijie Huaren Xiaohua Zazhi 2010; 18(13): 1380-1383 [DOI: 10.11569/wcjd.v18.i13.1380] [Reference Citation Analysis]
20 Buti M, García-samaniego J, Prieto M, Rodríguez M, Sánchez-tapias JM, Suárez E, Esteban R. Documento de consenso de la AEEH sobre el tratamiento de la infección por el virus de la hepatitis B (2012). Gastroenterología y Hepatología 2012;35:512-28. [DOI: 10.1016/j.gastrohep.2012.04.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
21 Long JD, Rutledge SM, Sise ME. Autoimmune Kidney Diseases Associated with Chronic Viral Infections. Rheum Dis Clin North Am 2018;44:675-98. [PMID: 30274630 DOI: 10.1016/j.rdc.2018.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
22 Trépo C, Amiri M, Guillevin L. Extrahepatic Manifestations of Hepatitis B Infection. In: Thomas HC, Lok AS, Locarnini SA, Zuckerman AJ, editors. Viral Hepatitis. Oxford: John Wiley & Sons, Ltd; 2013. pp. 154-62. [DOI: 10.1002/9781118637272.ch11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Yang Y, Ma YP, Chen DP, Zhuo L, Li WG. A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy. PLoS One 2016;11:e0160437. [PMID: 27598699 DOI: 10.1371/journal.pone.0160437] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
24 Cholongitas E, Tziomalos K, Pipili C. Management of patients with hepatitis B in special populations. World J Gastroenterol 2015; 21(6): 1738-1748 [PMID: 25684938 DOI: 10.3748/wjg.v21.i6.1738] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
25 Naicker S, Fabian J, Naidoo S, Wadee S, Paget G, Goetsch S. Infection and glomerulonephritis. Semin Immunopathol 2007;29:397-414. [PMID: 17846774 DOI: 10.1007/s00281-007-0088-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
26 Zheng XY, Wei RB, Tang L, Li P, Zheng XD. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol 2012; 18(8): 821-832 [PMID: 22371643 DOI: 10.3748/wjg.v18.i8.821] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
27 Cacoub P, Terrier B. Hepatitis B-related autoimmune manifestations. Rheum Dis Clin North Am. 2009;35:125-137. [PMID: 19481001 DOI: 10.1016/j.rdc.2009.03.006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
28 Rapti IN, Hadziyannis SJ. Treatment of special populations with chronic hepatitis B infection. Expert Review of Gastroenterology & Hepatology 2014;5:323-39. [DOI: 10.1586/egh.11.7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
29 Ebata S, Hashimoto S, Suzuki A, Ito M, Maoka T, Ishikawa Y, Mochizuki T, Koike T. A case of adefovir-induced membranous nephropathy related to hepatitis B caused by lamivudine-resistant virus after liver transplant due to Byler's disease. Clin Exp Nephrol 2012;16:805-10. [PMID: 22911115 DOI: 10.1007/s10157-012-0680-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Fu B, Ji Y, Hu S, Ren T, Bhuva MS, Li G, Yang H. Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis. PLoS One 2020;15:e0227532. [PMID: 31940324 DOI: 10.1371/journal.pone.0227532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Kataoka H, Mochizuki T, Akihisa T, Kawasoe K, Kawachi K, Makabe S, Sawada A, Manabe S, Sato M, Amemiya N, Mitobe M, Akanuma T, Ito Y, Inoue T, Suzuki T, Matsui K, Moriyama T, Horita S, Ohara M, Honda K, Nitta K. Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report. Medicine (Baltimore) 2019;98:e14014. [PMID: 30633192 DOI: 10.1097/MD.0000000000014014] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Liu CH, Kao JH. Editorial: nephrotoxicity and oral anti-viral therapy for HBV-facts or fiction? Aliment Pharmacol Ther 2019;49:229-30. [PMID: 30589963 DOI: 10.1111/apt.15056] [Reference Citation Analysis]
33 Wong F. Renal diseases and the liver. Clin Liver Dis 2011;15:39-53. [PMID: 21111992 DOI: 10.1016/j.cld.2010.09.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
34 Shah AS, Amarapurkar DN. Spectrum of hepatitis B and renal involvement. Liver Int. 2018;38:23-32. [PMID: 28627094 DOI: 10.1111/liv.13498] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]